Korean J Fam Pract. 2016; 6(6): 668-674  https://doi.org/10.21215/kjfp.2016.6.6.668
The Association between Overactive Bladder Symptom Score and International Prostate Symptom Score in a Male Population over the Middle Age
Yun-Ah Song1, Su-Bin Jung2, Do-Heun Chung3, Byung-Keun Choi3, Kyung-Suk Shin1,*, Choo-Yon Cho3, Sung-Ho Hong3, Jung-Eun Oh2, Yong-Jin Cho2, Byung-Wook Yoo3, Doo-Yong Son1, Sung-Ryul Shim4
1Department of Family Medicine, Soonchunhyang University Gumi Hospital, Gumi; 2Department of Family Medicine, Soonchunhyang University Cheonan Hospital, Cheonan; 3Department of Family Medicine, Soonchunhyang University Seoul Hospital, Seoul; 4Institute for Clinical Molecular Biology Research, Soonchunhyang University College of Medicine, Cheonan, Korea
Kyung-Suk Shin
Tel: +82-54-468-9113, Fax: +82-54-468-9032
E-mail: sks2001@schmc.ac.kr
Received: September 8, 2016; Revised: October 6, 2016; Accepted: October 15, 2016; Published online: December 20, 2016.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: The aim of this study was to investigate the correlation between the Overactive Bladder Symptom Score (OABSS) and International Prostate Symptom Score (IPSS).
Methods: A total of 250 male subjects aged 40 years and older were included in this cross-sectional study. One investigator, a clinical research associate, interviewed all participants using questionnaires for the IPSS, OABSS, and patient characteristics. Correlation analysis between IPSS and OABSS was used to assess the validity of OABSS with Pearson’s correlation coefficient. Internal consistency of the OABSS was evaluated using Cronbach’s α.
Results: The means of total IPSS and OABSS scores were 10.38±8.65 and 3.44±3.49, respectively. Pearson’s correlation coefficient for total IPSS and OABSS was 0.773, and the coefficient for IPSS storage and OABSS was 0.864, which is high. For each of the storage symptoms (frequency, nocturia, urgency), the coefficients for IPSS and OABSS showed a high correlation. All values were statistically significant (P<0.001). For severity, the coefficients for IPSS storage symptoms in the mild, moderate, and severe groups and the OABSS were 0.721, 0.724, and 0.616, respectively (P<0.001). The result of Cronbach’s α test for internal consistency was 0.731 for the OABSS questionnaire, indicating an acceptable degree of internal consistency.
Conclusion: OABSS was found to have a high degree of correlation with IPSS. Our results suggest that IPSS can aid in screening of OAB.
Keywords: Overactive Bladder; Urinary Bladder, Overactive; Prostatic Hyperplasia, Benign; Questionnaires; International Prostate Symptom Score; Overactive Bladder Symptom Score
References
  1. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Populationbased survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14; discussion 1314-5.
    Pubmed CrossRef
  2. Okamura K, Usami T, Nagahama K, Maruyama S, Mizuta E. “Quality of life” assessment of urination in elderly Japanese men and women with some medical problems using International Prostate Symptom Score and King’s Health Questionnaire. Eur Urol 2002; 41: 411-9.
    CrossRef
  3. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
    Pubmed CrossRef
  4. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079-86.
    Pubmed CrossRef
  5. Homma Y, Gotoh M. Symptom severity and patient perceptions in overactive bladder: how are they related? BJU Int 2009; 104: 968-72.
    Pubmed CrossRef
  6. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology 2006; 68: 318-23.
    Pubmed CrossRef
  7. Gotoh M, Homma Y, Yokoyama O, Nishizawa O. Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology 2011; 78: 768-73.
    Pubmed CrossRef
  8. Homma Y, Kakizaki H, Yamaguchi O, Yamanishi T, Nishizawa O, Yokoyama O, et al. Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. Urology 2011;77: 60-4.
    Pubmed CrossRef
  9. Jeong SJ, Homma Y, Oh SJ. Korean version of the overactive bladder symptom score questionnaire: translation and linguistic validation. Int Neurourol J 2011; 15: 135-42.
    Pubmed KoreaMed CrossRef
  10. Kubota Y, Kojima Y, Shibata Y, Imura M, Kohri K, Sasaki S. Correlation between improvements in overactive bladder symptom score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug. Neurourol Urodyn 2011; 30: 1309-14.
    CrossRef
  11. Tanaka Y, Masumori N, Tsukamoto T. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. Int J Urol 2010; 17: 796-800.
    Pubmed CrossRef
  12. Tsujimura A, Takao T, Miyagawa Y, Yamamoto K, Fukuhara S, Nakayama J, et al. Urgency is an independent factor for sleep disturbance in men with obstructive sleep apnea. Urology 2010; 76: 967-70.
    Pubmed CrossRef
  13. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology 2010; 76: 835-40.
    Pubmed CrossRef
  14. Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gómez JM, Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 2008; 62: 1076-86.
    Pubmed KoreaMed CrossRef
  15. Sagnier PP, MacFarlane G, Richard F, Botto H, Teillac P, Boyle P. Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 1994; 151:1266-70.
    Pubmed
  16. Tsukamoto T, Kumamoto Y, Masumori N, Miyake H, Rhodes T, Girman CJ, et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995; 154: 391-5.
    CrossRef
  17. Choi HR, Chung WS, Shim BS, Kwon SW, Hong SJ, Chung BH, et al. Translation validity and reliability of I-PSS Korean version. Korean J Urol 1996;37: 659-65.
  18. Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57; discussion 64.
    Pubmed
  19. Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki H, et al. Clinical guidelines for overactive bladder. Int J Urol 2009; 16: 126-42.
    Pubmed CrossRef
  20. Jeong SJ, Homma Y, Oh SJ. Reproducibility study of overactive bladder symptom score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms. Qual Life Res 2014;23: 285-92.
    Pubmed CrossRef
  21. Weinberg AC, Brandeis GH, Bruyere J, Tsui JF, Weiss JP, Rutman MP, et al. Reliability and validity of the overactive bladder symptom score in Spanish (OABSS-S). Neurourol Urodyn 2012; 31: 664-8.
    Pubmed CrossRef
  22. Hung MJ, Chou CL, Yen TW, Chuang YC, Meng E, Huang ST, et al. Development and validation of the Chinese overactive bladder symptom score for assessing overactive bladder syndrome in a RESORT study. J Formos Med Assoc 2013; 112: 276-82.
    Pubmed CrossRef


This Article

e-submission

Archives